Sugi Predict

Sugi Predict / Compounds / SCHEMBL7138784

SCHEMBL7138784

SCHEMBL7138784

CCOC(=O)CC(NC(=O)OC(C)(C)C)c1ccc(NC(=O)c2csc(NC(=O)NCc3ccccc3)n2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.42
▸ TP53 P04637 1/20 0.42
▸ MAPT P10636 7/20 0.41
▸ NAMPT P43490 1/20 0.41
▸ PTPRB P23467 1/20 0.40
▸ TDP1 Q9NUW8 4/20 0.40
▸ KDM4E B2RXH2 3/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ PPID Q08752 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ ROCK2 O75116 1/20 0.40
▸ ROCK1 Q13464 1/20 0.40
▸ ALDH1A1 P00352 2/20 0.39
▸ ABCB1 P08183 1/20 0.39
▸ PTPN1 P18031 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ ITGB3 P05106 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7144223 0.91 ROCK2 (0.42) LMNAMAPTNAMPTPTPRBTDP1
SCHEMBL7144238 0.91 ROCK2 (0.42) LMNAMAPTNAMPTPTPRBTDP1
SCHEMBL7138766 0.89 LMNA (0.44) LMNATP53MAPTNAMPTRAB9A
SCHEMBL7147820 0.86 LMNA (0.48) LMNATP53MAPTNAMPTKDM4E
SCHEMBL7143549 0.85 LMNA (0.46) LMNATP53MAPTNAMPTTDP1
SCHEMBL7139124 0.83 ALDH1A1 (0.43) LMNATP53MAPTNAMPTRAB9A
SCHEMBL7658978 0.81 ITGB3 (0.42) LMNAMAPTNAMPTRAB9ANPC1
SCHEMBL7658972 0.81 ITGB3 (0.42) LMNAMAPTNAMPTRAB9ANPC1
SCHEMBL7137162 0.81 MAPT (0.50) MAPTPTPRBTDP1KDM4EMAPK1
SCHEMBL7140433 0.81 MAPT (0.50) MAPTPTPRBTDP1KDM4EMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6320054-B1 INHIBIT BINDING OF ADHESIVE PROTEINS TO THE SURFACE OF DIFFERENT TYPES F CELL AND ACCORDINGLY INFLUENCE CELL-CELL AND CELL-MATRIX INTERACTIONS. HOFFMAN-LA ROCHE INC. 2001-11-20 — — US claimed
EP-0928790-B1 Thiazole derivatives HOFFMANN LA ROCHE (CH) 2003-03-05 — — EP disclosed
US-6344562-B1 ANTITUMOR AGENTS HOFFMANN-LA ROCHE INC. 2002-02-05 — — US disclosed
US-20020010316-A1 Thiazole derivatives ALIG LEO (CH) 2002-01-24 — — US disclosed
US-6320054-B1 INHIBIT BINDING OF ADHESIVE PROTEINS TO THE SURFACE OF DIFFERENT TYPES F CELL AND ACCORDINGLY INFLUENCE CELL-CELL AND CELL-MATRIX INTERACTIONS. HOFFMAN-LA ROCHE INC. 2001-11-20 — — US disclosed
US-6100282-A Thiazole derivatives HOFFMAN-LA ROCHE INC. (US) 2000-08-08 — — US disclosed
EP-0928790-A1 Thiazole derivatives F. HOFFMANN-LA ROCHE AG (CH) 1999-07-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010316-A1 Thiazole derivatives VCAM1, SOST, TGFB1 LMNA 3184/4885TP53 525/4885MAPT 86/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.